Human Vaccines Market to Expand at a Noteworthy CAGR of 11.8% during Forecast 2016 to 2022

Rising Prevalence of Infectious Diseases to Drive the Global Human Vaccines Market at a CAGR of 5.72% During the Forecast Period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Human Vaccines Market” that contains information from 2025 to 2035. The Human Vaccines Market is estimated to register a CAGR of 5.72% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Human Vaccines Market — Pfizer Inc. (US), Merck & Co. (US), AbbVie Inc. (US), Roche Holding AG (Switzerland), Gilead Sciences Inc. (US), Johnson & Johnson (US), Bristol Myers Squibb (US), Novartis AG (Switzerland), Regeneron Pharmaceuticals (US), Bayer AG (Germany), Moderna Inc. (US), AstraZeneca Plc (UK), GlaxoSmithKline Plc (UK), and Sanofi (France).

Market Highlights

The Global Human Vaccines Market is accounted for to register a CAGR of 5.72% during the forecast period and is estimated to reach USD 1.23 Billion by 2035.

The market is growing mostly because more people are getting sick with infectious diseases, more people are aware of the benefits of vaccines, and the government is doing a lot to promote immunization programs. Also, big investments in research and development (R&D), especially in mRNA and recombinant vaccine technologies, are changing the way vaccines are made.

Partnerships between the public and private sectors, like those between global health agencies, research institutions, and vaccine manufacturers, have sped up the development and distribution of vaccines. For example, partnerships that started during the COVID-19 pandemic showed how working together can make vaccines easier to get and make them more efficiently.

Furthermore, the implementation of personalized and therapeutic vaccines aimed at oncological and autoimmune diseases is gaining momentum. These changes, along with the introduction of advanced delivery systems (such as intramuscular, subcutaneous, oral, and intradermal routes), are broadening the uses of vaccines beyond just preventing disease.

Governments all over the world, with help from groups like the World Health Organization (WHO), are still putting universal vaccination programs into place to raise immunization rates and improve health outcomes, especially in developing areas.

Segment Analysis

The Global Human Vaccines Market has been segmented based on Vaccine Type, Application, Administration Route, Target Diseases, and Region.

Based on Vaccine Type, the market has been segmented into Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid vaccines. Among these, the Inactivated vaccine segment held the largest market share in 2024, valued at USD 15.0 Billion, and is projected to reach USD 23.0 Billion by 2035. This dominance is attributed to its strong safety profile and broad application across multiple infectious diseases. The Live Attenuated segment is expected to grow significantly, reaching USD 15.5 Billion by 2035, due to its high efficacy and ability to induce long-term immunity.

Based on Application, the market has been segmented into Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Influenza Vaccines. The Preventive Vaccines segment dominated the market in 2024, driven by global immunization programs and government-led health initiatives. The Therapeutic Vaccines segment is anticipated to grow at a steady rate owing to ongoing research in cancer and chronic disease vaccines.

Based on the Administration Route, the market is categorized into Intramuscular, Subcutaneous, Oral, and Intradermal. The Intramuscular route accounted for the largest market share in 2024 due to its effectiveness and rapid immune response, while the Oral segment is expected to expand fastest, given its ease of administration and patient compliance.

Based on Target Diseases, the market is divided into Infectious Diseases, Oncological Diseases, and Autoimmune Diseases. The Infectious Diseases segment dominated the market in 2024, while the Oncological Diseases segment is projected to record robust growth during the forecast period, supported by the rising prevalence of cancer and the development of therapeutic vaccines.

Regional Analysis

By region, the Human Vaccines Market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East & Africa (MEA). North America held the largest share of the global Human Vaccines Market in 2024, valued at USD 20.0 Billion, and is projected to reach USD 32.0 billion by 2035. The regional dominance is attributed to strong research and development investments, well-established healthcare infrastructure, and active participation of leading vaccine manufacturers such as Pfizer, Moderna, and Johnson & Johnson. The U.S. continues to lead due to robust government funding and a high rate of immunization coverage.

Key Findings of the Study

• The Global Human Vaccines Market is expected to reach USD 1.23 billion by 2035, registering a CAGR of 5.72% during the forecast period.


• North America accounted for the largest market share in 2024, while Asia-Pacific is projected to grow at the fastest rate during the forecast period.


• Based on Vaccine Type, the Inactivated segment held the largest market share in 2024.


• Based on Application, the Preventive Vaccines segment dominated the market in 2024.


• Based on the Administration Route, the Intramuscular segment accounted for the highest share in 2024.


• Key market players include Pfizer, Merck & Co., AbbVie, Roche, Gilead Sciences, Johnson & Johnson, Bristol Myers Squibb, Novartis, Regeneron Pharmaceuticals, Bayer, Moderna, AstraZeneca, GlaxoSmithKline, and Sanofi.

Related Reports